IOVANCE BIOTHERAPEUTICS ($IOVA) posted quarterly earnings results for Q4 2025 on Tuesday, February 24th. The company reported earnings of -$0.18 per share, missing estimates of -$0.18 by $0.00. The company also reported revenue of $86,710,000, beating estimates of $82,321,548 by $4,388,452.
You can see Quiver Quantitative's $IOVA stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
IOVANCE BIOTHERAPEUTICS Hedge Fund Activity
We have seen 149 institutional investors add shares of IOVANCE BIOTHERAPEUTICS stock to their portfolio, and 136 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BANK OF AMERICA CORP /DE/ added 7,998,583 shares (+127.4%) to their portfolio in Q4 2025, for an estimated $21,836,131
- STATE STREET CORP added 6,851,486 shares (+51.5%) to their portfolio in Q4 2025, for an estimated $18,704,556
- HRT FINANCIAL LP added 3,986,314 shares (+1078.3%) to their portfolio in Q4 2025, for an estimated $10,882,637
- D. E. SHAW & CO., INC. added 3,753,586 shares (+4925.4%) to their portfolio in Q4 2025, for an estimated $10,247,289
- MORGAN STANLEY added 3,610,277 shares (+64.7%) to their portfolio in Q4 2025, for an estimated $9,856,056
- BLACKROCK, INC. added 3,561,836 shares (+13.7%) to their portfolio in Q4 2025, for an estimated $9,723,812
- VANGUARD GROUP INC added 3,148,096 shares (+13.1%) to their portfolio in Q4 2025, for an estimated $8,594,302
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
IOVANCE BIOTHERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $IOVA in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Barclays issued a "Overweight" rating on 11/24/2025
- Chardan Capital issued a "Buy" rating on 11/06/2025
- HC Wainwright & Co. issued a "Buy" rating on 10/29/2025
To track analyst ratings and price targets for IOVANCE BIOTHERAPEUTICS, check out Quiver Quantitative's $IOVA forecast page.
IOVANCE BIOTHERAPEUTICS Price Targets
Multiple analysts have issued price targets for $IOVA recently. We have seen 3 analysts offer price targets for $IOVA in the last 6 months, with a median target of $10.0.
Here are some recent targets:
- Etzer Darout from Barclays set a target price of $10.0 on 12/17/2025
- Geulah Livshits from Chardan Capital set a target price of $17.0 on 11/06/2025
- Joseph Pantginis from HC Wainwright & Co. set a target price of $9.0 on 10/29/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
